Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 9/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915583 | 0.92 | S1PR2 (0.38) | HTTHSD17B10S1PR2XDHPTGER4 | |
| SCHEMBL23909100 | 0.87 | S1PR2 (0.37) | S1PR2XDHNPC1USP30 | |
| SCHEMBL23914864 | 0.86 | S1PR2 (0.43) | S1PR2DGAT1XDHNPC1PTGER4 | |
| SCHEMBL23909067 | 0.85 | S1PR2 (0.37) | S1PR2XDHNPC1USP30 | |
| SCHEMBL23908892 | 0.84 | S1PR2 (0.42) | S1PR2XDHNPC1 | |
| SCHEMBL23909126 | 0.82 | S1PR2 (0.40) | S1PR2NPC1 | |
| SCHEMBL23909053 | 0.81 | S1PR2 (0.42) | S1PR2XDHNPC1 | |
| SCHEMBL23914772 | 0.80 | S1PR2 (0.38) | S1PR2XDH | |
| SCHEMBL23908843 | 0.77 | XDH (0.39) | HTTHSD17B10DGAT1XDH | |
| SCHEMBL23909001 | 0.77 | XDH (0.38) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | HTT 4536/4885HSD17B10 2447/4885S1PR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.